Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Update

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) was the target of a significant increase in short interest during the month of February. As of February 27th, there was short interest totaling 11,389 shares, an increase of 25.6% from the February 12th total of 9,071 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average daily trading volume, of 20,191 shares, the short-interest ratio is currently 0.6 days. Based on an average daily trading volume, of 20,191 shares, the short-interest ratio is currently 0.6 days. Currently, 0.0% of the shares of the company are sold short.

Pharming Group Stock Performance

Shares of Pharming Group stock traded down $0.63 during trading on Friday, hitting $14.51. 35,943 shares of the company’s stock were exchanged, compared to its average volume of 20,159. The stock has a market capitalization of $1.02 billion, a price-to-earnings ratio of 1,451.00 and a beta of 0.04. The business has a 50-day simple moving average of $17.21 and a 200-day simple moving average of $16.09. Pharming Group has a 52-week low of $7.50 and a 52-week high of $21.34. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.03 and a current ratio of 2.59.

Pharming Group (NASDAQ:PHAR) last announced its quarterly earnings results on Thursday, March 12th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.08). The company had revenue of $106.50 million for the quarter, compared to analyst estimates of $111.76 million. Pharming Group had a return on equity of 1.08% and a net margin of 0.71%. On average, research analysts forecast that Pharming Group will post -0.2 EPS for the current year.

Key Pharming Group News

Here are the key news stories impacting Pharming Group this week:

• Positive Sentiment: Company set a 2026 revenue target of $405M–$425M, citing growth from Joenja and RUCONEST as primary drivers — this provides clear growth levers for next year and supports upside if execution meets targets. Pharming outlines $405M–$425M 2026 revenue target
• Positive Sentiment: Company reported full-year and Q4 2025 revenue growth and positive cash flow and reaffirmed 2026 guidance — fundamentals showing improving cash generation can reduce funding risk and support valuation. Pharming Group reports fourth quarter and full year 2025 financial results
• Positive Sentiment: Oppenheimer reiterated an “Outperform” rating with a $41 price target (slightly trimmed), signaling continued bullish analyst conviction and implying substantial upside from current levels. Oppenheimer reaffirms outperform on PHAR
• Neutral Sentiment: HC Wainwright maintains a Buy rating and $37 target but lowered FY2026 EPS from $0.49 to $0.35 — the firm still expects material 2026 profitability, but the cut shows some model uncertainty around timing and magnitude of margin expansion. HC Wainwright updates estimates for PHAR
• Negative Sentiment: Q4 results missed expectations: revenue $106.5M vs. analyst ~$111.8M and EPS $0.07 vs. $0.15 expected — the quarter’s misses likely triggered the intraday sell-off despite upbeat guidance. Pharming Q4 2025 press release

Analysts Set New Price Targets

A number of brokerages have recently weighed in on PHAR. Weiss Ratings lowered shares of Pharming Group from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday. Wall Street Zen raised Pharming Group to a “strong-buy” rating in a research report on Saturday, December 27th. Zacks Research downgraded Pharming Group from a “hold” rating to a “strong sell” rating in a research note on Thursday. HC Wainwright set a $37.00 price objective on Pharming Group and gave the company a “buy” rating in a report on Thursday. Finally, Oppenheimer restated an “outperform” rating and issued a $41.00 price objective (down from $42.00) on shares of Pharming Group in a research note on Friday. Two investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $39.00.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of PHAR. EverSource Wealth Advisors LLC acquired a new position in Pharming Group in the second quarter valued at approximately $32,000. SmartHarvest Portfolios LLC acquired a new stake in shares of Pharming Group during the 4th quarter worth approximately $224,000. Millennium Management LLC acquired a new stake in shares of Pharming Group during the 4th quarter worth approximately $360,000. Finally, NewEdge Advisors LLC increased its holdings in shares of Pharming Group by 11,310.3% during the 4th quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock valued at $510,000 after purchasing an additional 28,615 shares in the last quarter. 0.03% of the stock is currently owned by hedge funds and other institutional investors.

Pharming Group Company Profile

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.